Burning Rock Biotech (BNR) Revenue (2019 - 2026)

Burning Rock Biotech's Revenue history runs 8 years deep, the most recent figure standing at $15.6 million for Q1 2026.

• In Q1 2026, Revenue fell 14.67% year-over-year to $15.6 million; the TTM figure through Mar 2026 stood at $72.9 million (changed 0.48% YoY), while the FY2025 annual figure was $77.2 million, up 9.18% from the prior year.
• Revenue for Q1 2026 stood at $15.6 million, down from $18.1 million in the prior quarter.
• The five-year high for Revenue was $21.7 million in Q3 2022, with the low at $15.6 million in Q1 2026.
• The 5-year median for Revenue is $18.5 million (2025), against an average of $18.9 million.
• The sharpest annual moves came in 2022 and 2023: Revenue surged 31.37% in 2022, then decreased 19.56% in 2023.
• Burning Rock Biotech's Revenue stood at $20.6 million in 2022, then fell by 17.3% to $17.1 million in 2023, then rose by 1.24% to $17.3 million in 2024, then rose by 4.62% to $18.1 million in 2025, then decreased by 13.36% to $15.6 million in 2026.
• Business Quant data shows BNR's Revenue at $15.6 million in Q1 2026, $18.1 million in Q4 2025, and $18.5 million in Q3 2025.